Nonalcoholic Fatty Liver Disease and Cardiovascular Risk
Published: April 14, 2022
- Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that affects more than 25% of adults worldwide.
- This scientific statement reviews the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease (ASCVD), diagnostic and screening strategies, and potential interventions.
- By increasing awareness of NAFLD, facilitating better access to reliable imaging tools for screening for NAFLD, and the development of proven tools for treatment of NAFLD, the rising tide of non-alcoholic steatohepatitis (NASH) and more advanced hepatic disease can be reversed and adverse ASCVD outcomes prevented.
Supporting Materials
- Commentary: Non-alcoholic Fatty Liver Disease and Cardiovascular Risk: Much More Than “Foie Gras” by Raul D. Santos MD, PhD, MSc
- Top Things to Know: Nonalcoholic Fatty Liver Disease and Cardiovascular Risk
- Nonalcoholic Fatty Liver Disease and CV Risk Patient Handout (PDF)
- News Release: About 1 in 4 adults has an often-missed liver disorder linked to higher heart disease risk